Uncategorized

The ratings agency said healthcare’s vulnerable state makes it “target rich,” which could bring service disruptions and personal data disclosures.

The order is the latest twist in an escalating legal battle over access to mifepristone, a fight that is headed to the Supreme Court.

New therapeutics for Major Depressive Disorder could change the treatment landscape and give patients more options.

Climbing expenses and investment losses contributed to the drop, compared with net income of $1.8 billion in 2021.

The lawsuit, brought by Arbutus Biopharma, marks the latest legal action in an ongoing battle for intellectual property underlying mRNA vaccines for COVID-19.

Parth Mehrotra will succeed Shawn Morris, who led the company through its 2021 initial public offering.

The analysts are “leaning into increased medtech exposure” after determining that several challenges that have constrained the industry are easing.

People who used an over-the-counter hearing aid for six weeks saw similar results to people who used an audiologist-fitted device, suggesting less costly, self-fitted hearing aids could be an option. 

The company has several targeted therapeutics in early-stage trials and preclinical development for cancer types with high expression levels of the protein.

ATMA Journey Centers Inc. is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada.